ArticleJournal of inflammation research2024
Case Series on the Efficacy and Safety of Tocilizumab in IVIG-Resistant Kawasaki Disease: A Retrospective Analysis of Five Patients.
Article in Journal of inflammation research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Targeting STAT3 pathway attenuates macrophages inflammation and cardiovascular injury in a model of Kawasaki disease.Scientific reports · 2026Article
- Multiomics approaches in Kawasaki disease: insights into pathogenesis and emerging directions for diagnosis and treatment.Clinical and experimental pediatrics · 2026Article
- Tocilizumab for the Treatment of Intravenous Immunoglobulin-Resistant Kawasaki Disease in Children: Two Case Reports and Literature Review.Journal of inflammation research · 2026Article
- The correlation and auxiliary diagnostic value of gut microbiota and serological indicators with Kawasaki disease complicated by coronary artery lesions.Frontiers in cellular and infection microbiology · 2026Article
- Favorable coronary outcomes following IL-6 blockade with tocilizumab in IVIG-resistant kawasaki disease: a case series.Frontiers in immunology · 2026Article
- Immunophenotype of Kawasaki Disease: Insights into Pathogenesis and Treatment Response.Life (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Kawasaki disease (KD) is a leading cause of acquired heart disease in children in developed countries. While intravenous immunoglobulin (IVIG) is the standard treatment, 10-20% of patients do not respond to IVIG. Given the significant role of interleukin-6 (IL-6) in KD pathophysiology, targeting IL-6 may offer a therapeutic option for IVIG-resistant KD. Objective: This study aims to evaluate the efficacy and safety of tocilizumab (an IL-6 receptor antagonist) in the treatment of IVIG-resistant KD through a retrospective analysis of clinical data. Methods: Clinical data from five KD patients treated with tocilizumab (TCZ) at Jiangxi Children's Hospital from January 2023 to February 2024 were retrospectively analyzed. All patients met the 2017 American Heart Association diagnostic criteria for KD and received a single dose of TCZ. Data on clinical manifestations, laboratory indicators, and coronary artery changes before and after TCZ treatment were collected. Results: Four of the five patients had a KOBAYASHI score >4, and initial IVIG and glucocorticoid treatments were ineffective. Following TCZ administration, body temperature normalized within 12 hours in three patients, and inflammatory markers, including C-reactive protein and interleukin-6, returned to normal levels. Coronary artery dilation was observed in 75% of patients pre-TCZ; post-TCZ, coronary arteries normalized in three patients, while one patient experienced progressive right coronary artery dilation. No adverse events were reported following TCZ administration. Conclusion: Tocilizumab effectively controls systemic inflammation and improves coronary artery outcomes in IVIG-resistant KD patients, with no observed adverse events. Larger studies are necessary to confirm these findings and further investigate long-term effects on coronary artery health.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.